Tempus AI Inc (TEM)

Tempus AI Inc. is a healthcare technology company listed on NASDAQ under the ticker TEM. The company develops tools and services that connect clinical workflows with diagnostics, analytics, and multimodal data. Its Tempus platform links a clinician’s desktop with laboratory capabilities and data resources, while Hub is designed to support healthcare providers using next-generation sequencing tests. Tempus also offers Lens for life sciences and precision research, along with diagnostics services that include NGS diagnostics, PCR profiling, and anatomic and molecular pathology testing. Its broader portfolio includes large-panel solid tumor and hematologic assays, inherited-condition genetic tests, pharmacogenomic testing for certain psychiatric conditions, clinical trial matching through Trials, an AI platform called Next, and algorithm-based diagnostics applications through Algos. The company also licenses de-identified clinical, molecular, and imaging data through Insights and provides tumor-derived biological modeling through Organoids. Tempus AI maintains strategic collaborations with companies including AstraZeneca, Pathos AI, GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, and it also works with Blood Cancer United on a pediatric acute myeloid leukemia registry.

Jump directly to the stock analysis sections supported by the latest available data.